Newsletter
Every new paper in this field, in your inbox.
In patients with gastric cancer and positive peritoneal lavage cytology or localized peritoneal metastasis, upfront chemotherapy followed by surgery yields better outcomes than surgery followed by chemotherapy.
Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly enhances peritoneal metastasis-free survival and disease-free survival in patients with locally advanced colorectal cancer, though overall survival rates and complication rates remain unchanged.
Secondary cytoreductive surgery with hyperthermic intraperitoneal chemotherapy improves survival for select patients with recurrent colorectal cancer peritoneal metastases.
Surgeons should consider referral pathways, as many OOS patients previously deemed unresectable achieved complete cytoreduction at high-volume centers.
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) can significantly improve outcomes for patients with colorectal peritoneal metastases.
Laparoscopic exploration is vital for detecting occult peritoneal metastasis (opm) in gastric cancer, significantly impacting patient outcomes.
Surgeons need to consider that extensive perigastric dissection during cytoreductive surgery can impair postoperative recovery without affecting oncologic outcomes.
Experts established clear guidelines for handling gastric cancer with peritoneal metastasis, crucial for improving patient outcomes.
Robotic cytoreduction and HIPEC can improve recovery in gastric cancer patients with limited peritoneal metastasis.
Neoadjuvant chemotherapy before CRS/HIPEC for metachronous colorectal peritoneal metastases offers no survival benefit and increases complication risks.
